Table 1.
Baseline Characteristics of the Patients, According to Study Group.*
| Characteristic | All Eligible Patients | Patients with 2-Yr Data on Ovarian Failure | ||||
|---|---|---|---|---|---|---|
| Overall (N = 218) | Chemotherapy Alone (N = 113) | Chemotherapy plus Goserelin (N = 105) | Overall (N = 135) | Chemotherapy Alone (N = 69) | Chemotherapy plus Goserelin (N = 66) | |
| Age | ||||||
|
| ||||||
| Median (range) | 37.7 (25.1–49.9) | 38.7 (25.1–49.9) | 37.6 (26.1–48.6) | 36.9 (25.1–49.9) | 37.5 (25.1–49.9) | 36.1 (26.1–48.6) |
|
| ||||||
| <40 yr — no. (%) | 138 (63) | 70 (62) | 68 (65) | 94 (70) | 45 (65) | 49 (74) |
|
| ||||||
| ≥40 yr — no. (%) | 80 (37) | 43 (38) | 37 (35) | 41 (30) | 24 (35) | 17 (26) |
|
| ||||||
| Race or ethnic group — no./total no. (%)† | ||||||
|
| ||||||
| White | 122/136 (90) | 57/66 (86) | 65/70 (93) | 69/79 (87) | 33/39 (85) | 36/40 (90) |
|
| ||||||
| Black | 11/136 (8) | 6/66 (9) | 5/70 (7) | 7/79 (9) | 3/39 (8) | 4/40 (10) |
|
| ||||||
| Asian | 2/136 (1) | 2/66 (3) | 0 | 2/79 (3) | 2/39 (5) | 0 |
|
| ||||||
| Native American | 1/136 (1) | 1/66 (2) | 0 | 1/79 (1) | 1/39 (3) | 0 |
|
| ||||||
| Unknown | 82/218 (38) | 47/113 (42) | 35/105 (33) | 56/135 (41) | 30/69 (43) | 26/66 (39) |
|
| ||||||
| Hispanic or non-Hispanic ethnic group — no./total no. (%)† | ||||||
|
| ||||||
| Hispanic | 67/126 (53) | 26/60 (43) | 33/66 (50) | 39/71 (55) | 18/35 (51) | 14/36 (39) |
|
| ||||||
| Non-Hispanic | 59/126 (47) | 34/60 (57) | 33/66 (50) | 32/71 (45) | 17/35 (49) | 22/36 (61) |
|
| ||||||
| Unknown | 92/218 (42) | 53/113 (47) | 39/105 (37) | 64/135 (47) | 34/69 (49) | 30/66 (45) |
|
| ||||||
| Planned chemotherapy — no. (%) | ||||||
|
| ||||||
| 3–4 cycles of anthracycline-based therapy | 46 (21) | 22 (19) | 24 (23) | 27 (20) | 15 (22) | 12 (18) |
|
| ||||||
| 3–4 cycles of nonanthracycline-based therapy | 12 (6) | 7 (6) | 5 (5) | 8 (6) | 5 (7) | 3 (5) |
|
| ||||||
| 6–8 cycles of anthracycline-based therapy | 152 (70) | 80 (71) | 72 (69) | 96 (71) | 47 (68) | 49 (74) |
|
| ||||||
| 6–8 cycles of nonanthracycline-based therapy | 8 (4) | 4 (4) | 4 (4) | 4 (3) | 2 (3) | 2 (3) |
|
| ||||||
| Stage of cancer — no. (%) | ||||||
|
| ||||||
| I | 55 (25) | 32 (28) | 23 (22) | 34 (25) | 18 (26) | 16 (24) |
|
| ||||||
| II | 107 (49) | 52 (46) | 55 (52) | 70 (52) | 34 (49) | 36 (55) |
|
| ||||||
| IIIA | 54 (25) | 29 (26) | 25 (24) | 31 (23) | 17 (25) | 14 (21) |
|
| ||||||
| Unknown | 2 (1) | 0 | 2 (2) | 0 | 0 | 0 |
|
| ||||||
| HER2 status — no./total no. (%) | ||||||
|
| ||||||
| Positive | 32/215 (15) | 19/112 (17) | 13/103 (13) | 23/132 (17) | 11/68 (16) | 12/64 (19) |
|
| ||||||
| Negative | 183/215 (85) | 93/112 (83) | 90/103 (87) | 109/132 (83) | 57/68 (84) | 52/64 (81) |
|
| ||||||
| Unknown | 3/218 (1) | 1/113 (1) | 2/105 (2) | 3/135 (2) | 1/69 (1) | 2/66 (3) |
*
Among patients with 2-year end-point data, there were no significant differences between the groups in any of the characteristics listed in this table. Percentages may not sum to 100% for a given characteristic owing to rounding. HER2 denotes human epidermal growth factor receptor 2.
†
Data on race and ethnic group were self-reported or were reported by the investigator. Data on race and ethnic group were not collected at many of the sites outside the United States; for patients at those sites, data were recorded as unknown.